Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1.

Area of Science:

• Immunology
• Cancer immunotherapy
• T cell biology

Background:

• Immune checkpoint inhibitors, including anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), are vital cancer treatments.
• The precise impact of these therapies on T cell differentiation and the subsequent immunological memory response is not fully understood.

Purpose of the Study:

• To investigate how anti-CTLA-4 and anti-PD-1 influence the formation and characteristics of memory T cells.
• To elucidate the roles of T cell factor-1 (TCF-1) and thymocyte selection-associated high mobility group box (TOX) in mediating the memory responses induced by these checkpoint inhibitors.

Main Methods:

• Comparative analysis of memory T cell formation in mice treated with anti-CTLA-4 versus anti-PD-1.
• Assessment of T cell expansion, cytokine production, and antitumor activity.
• Utilizing conditional knockout mouse models for Tcf7 and Tox to determine their specific contributions.

Main Results:

• Memory T cells generated by anti-CTLA-4 showed enhanced expansion, cytokine production, and antitumor efficacy compared to anti-PD-1.
• Anti-CTLA-4 treatment preserved more TCF-1+ T cells, whereas anti-PD-1 treatment resulted in a higher proportion of TOX+ T cells.
• TCF-1 was essential for the anti-CTLA-4-mediated memory response, while TOX deletion did not affect the anti-PD-1 response.

Conclusions:

• Different immune checkpoint inhibitors induce distinct T cell differentiation pathways, leading to varied immunological memory.
• Understanding these distinct mechanisms is critical for optimizing cancer immunotherapy strategies and predicting long-term clinical outcomes.